Search

Nevertheless, treatment outcomes have only been reported in case reports and in a few clinical trials.2-4 The current study aimed to evaluate the efficacy and safety profile of peg IFN in the treatment of mycosis fungoides (MF). The only dose-limiting toxicity was a grade 3 elevation of liver enzymes in the 270-mg dose group.3 Overall, peg IFN should be considered as an alternative option in the treatment of MF and its optimal dosing needs to be evaluated in future studies. IFN- with its cytotoxic effects on tumorous T cells was introduced in the treatment of cutaneous T-cell lymphoma in the 1980s and is included as an option in CTCL guidelines.1 However, recombinant IFN a-2a or IFN a-2b interferon regimens are no longer available, and therefore, the pegylated analogue (pegylated IFN a-2a) has been currently used. [Extracted from the article]

A total of 40 specimens were collected as follows: thirty (75%) patients had patch type AA, seven (17.5%) had diffuse AA, and three (7.5%) had alopecia totalis. I Editor i Alopecia areata ( ) is an inflammatory disease of the hair follicle unit characterized by non-scarring hair loss. In the acute stage of our AA cases, pDCs were found in 30.8% which implies that the recruitment of pDCs in AA may appear gradually and then subside throughout the chronic stage. [Extracted from the article]

Background: Retinoids have long been used in the treatment of cutaneous T‐cell lymphomas. However, data on acitretin use for mycosis fungoides (MF) are very limited. Objectives: To evaluate treatment outcomes of acitretin in patients with MF attending three academic referral centres in different regions of Greece. Methods: Data on effectiveness, safety and drug survival of acitretin as monotherapy or as adjuvant regimen were collected in a multicentre, register‐based, retrospective study. Results: Overall, 128 patients (64.8% male; mean age at MF diagnosis 59.7 years) were included. Folliculotropic MF was present in 24 (18.8%) cases. Most patients (n = 118; 92.2%) had early‐stage disease (≤IIA) at acitretin initiation. In all, 28 (21.9%) patients received acitretin monotherapy, while 100 (78.1%) subjects on acitretin concomitantly received phototherapy (n = 65; 50.8%) or topical steroids (n = 27; 21.1%). Acitretin was given as a first‐line agent in 73 (57%) cases. A 77.3% overall response rate was noted: 44.5% and 32.8% for complete and partial responses, respectively. Acitretin was more effective as first‐line than as a subsequent agent (P = 0.008). A trend towards better response was observed in the combination arm compared to patients receiving acitretin alone (P = 0.056). Median time to best response was 6.9 months (IQR 4.4–9.4); median duration of response was 23.7 months (IQR 11.9–35.4). Overall, the mean length of all treatment patterns was 569 days (SD 718.8). Therapy was discontinued in 5 (3.9%) cases due to drug intolerance. Adverse effects were recorded in 62 (48.4%) cases with dyslipidaemia (n = 31; 24.2%), xerosis (n = 24; 18.6%) and hair loss (n = 10; 7.8%) being the most commonly recorded. Conclusions: Acitretin, either alone or as adjuvant, showed a stable long‐term effectiveness in this cohort, especially when used in the first‐line setting. This RAR‐selective agonist may serve as an attractive option for treatment of MF and should be further evaluated. [ABSTRACT FROM AUTHOR]

The article presents a case study of a 25-year-old female having T-cell lymphoma of γδ T-cell origin. It mentions that her first biopsy revealed a panniculitis with partial infiltration of dermis and subcutis with macrophages and small T lymphocytes and her second biopsy revealed lymphoid cells and epithelioid macrophages. Further it informs that she was subjected to syngeneic bone marrow transplantation.

Presents a letter to the editor in response to the article "Cystic Transformation of Seminiferous Tubules," published in the February 2005 issue of the journal "Histopathology."

Treatment of alopecia areata is often challenging, especially for patients with extended disease. Contact immunotherapy with diphenylcyclopropenone (DPCP) has been reported as an effective topical treatment but the exact immunologic mechanism of diverting the immune response is still unknown. We investigated the efficacy of topical immunotherapy with DPCD in acute, intermediate, and chronic lesions of AA and the response rate was associated with perifollicular infiltrate of T regulatory cells. Approximately two-thirds of our patients (67.5%) had a response rate > 50% after 6 months of DPCP therapy. Patients with acute and intermediate onset of the disease were more likely to respond to the therapy. Although responders demonstrated FOXP3+ positive lymphocytes in immunohistochemistry, this association could not be confirmed by statistical significance (p = 0.052). In patients with multiple lesions, that had different chronological onset, the lesions with more recent onset responded faster than lesions of longer duration., (© 2022 Wiley Periodicals LLC.)